Cynthia A Derdeyn1, Penny L Moore, Lynn Morris. 1. aEmory Vaccine Center at Yerkes National Primate Research Center bDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, USA cCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Services dUniversity of the Witwatersrand, Johannesburg eCenter for the AIDS Program of Research (CAPRISA), South Africa.
Abstract
PURPOSE OF REVIEW: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins. A current priority is to understand how bnAbs are generated during natural infection, and translate this information into immunogens that can elicit bnAb following vaccination. RECENT FINDINGS: Strain-specific neutralizing antibodies can acquire broad neutralizing capacity when the transmitted/founder Env or a specific Env variant is recognized by an unmutated rearranged germline that has the capacity to develop bnAb-like features. This event could be relatively infrequent, as only certain germlines appear to possess inherent features needed for bnAb activity. Furthermore, the glycosylation pattern and diversity of circulating HIV-1 Envs, as well as the state of the B-cell compartment, may influence the activation and maturation of certain antibody lineages. SUMMARY: Collectively, studies over the last year have suggested that the development of HIV-1 Env immunogens that bind and activate bnAb-like germlines is feasible. However, more information about the features of Env variants and the host factors that lead to breadth during natural infection are needed to elicit bnAbs through immunization.
PURPOSE OF REVIEW: Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1envelope (Env) glycoproteins. A current priority is to understand how bnAbs are generated during natural infection, and translate this information into immunogens that can elicit bnAb following vaccination. RECENT FINDINGS: Strain-specific neutralizing antibodies can acquire broad neutralizing capacity when the transmitted/founder Env or a specific Env variant is recognized by an unmutated rearranged germline that has the capacity to develop bnAb-like features. This event could be relatively infrequent, as only certain germlines appear to possess inherent features needed for bnAb activity. Furthermore, the glycosylation pattern and diversity of circulating HIV-1 Envs, as well as the state of the B-cell compartment, may influence the activation and maturation of certain antibody lineages. SUMMARY: Collectively, studies over the last year have suggested that the development of HIV-1Env immunogens that bind and activate bnAb-like germlines is feasible. However, more information about the features of Env variants and the host factors that lead to breadth during natural infection are needed to elicit bnAbs through immunization.
Authors: Rebecca M Lynch; Rong Rong; Saikat Boliar; Anurag Sethi; Bing Li; Joseph Mulenga; Susan Allen; James E Robinson; S Gnanakaran; Cynthia A Derdeyn Journal: J Virol Date: 2010-10-27 Impact factor: 5.103
Authors: Cecilia Rademeyer; Penny L Moore; Natasha Taylor; Darren P Martin; Isaac A Choge; Elin S Gray; Haynes W Sheppard; Clive Gray; Lynn Morris; Carolyn Williamson Journal: Virology Date: 2007-07-16 Impact factor: 3.616
Authors: Carolina B Ferreira; Alberto Merino-Mansilla; Anuska Llano; Ignacio Pérez; Isabel Crespo; Laia Llinas; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino Journal: J Virol Date: 2013-09-04 Impact factor: 5.103
Authors: Elin S Gray; M Anthony Moody; Constantinos Kurt Wibmer; Xi Chen; Dawn Marshall; Joshua Amos; Penny L Moore; Andrew Foulger; Jae-Sung Yu; Bronwen Lambson; Salim Abdool Karim; John Whitesides; Georgia D Tomaras; Barton F Haynes; Lynn Morris; Hua-Xin Liao Journal: J Virol Date: 2011-05-25 Impact factor: 5.103
Authors: Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn Journal: PLoS Pathog Date: 2009-09-18 Impact factor: 6.823
Authors: Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley Journal: Virology Date: 2017-03-06 Impact factor: 3.616
Authors: Sarah B Lloyd; Keith P Niven; Ben R Kiefel; David C Montefiori; Arnold Reynaldi; Miles P Davenport; Stephen J Kent; Wendy R Winnall Journal: Hum Vaccin Immunother Date: 2017-09-26 Impact factor: 3.452
Authors: M Anthony Moody; Feng Gao; Thaddeus C Gurley; Joshua D Amos; Amit Kumar; Bhavna Hora; Dawn J Marshall; John F Whitesides; Shi-Mao Xia; Robert Parks; Krissey E Lloyd; Kwan-Ki Hwang; Xiaozhi Lu; Mattia Bonsignori; Andrés Finzi; Nathan A Vandergrift; S Munir Alam; Guido Ferrari; Xiaoying Shen; Georgia D Tomaras; Gift Kamanga; Myron S Cohen; Noel E Sam; Saidi Kapiga; Elin S Gray; Nancy L Tumba; Lynn Morris; Susan Zolla-Pazner; Miroslaw K Gorny; John R Mascola; Beatrice H Hahn; George M Shaw; Joseph G Sodroski; Hua-Xin Liao; David C Montefiori; Peter T Hraber; Bette T Korber; Barton F Haynes Journal: Cell Host Microbe Date: 2015-09-09 Impact factor: 21.023
Authors: Natalia T Freund; Haoqing Wang; Louise Scharf; Lilian Nogueira; Joshua A Horwitz; Yotam Bar-On; Jovana Golijanin; Stuart A Sievers; Devin Sok; Hui Cai; Julio C Cesar Lorenzi; Ariel Halper-Stromberg; Ildiko Toth; Alicja Piechocka-Trocha; Harry B Gristick; Marit J van Gils; Rogier W Sanders; Lai-Xi Wang; Michael S Seaman; Dennis R Burton; Anna Gazumyan; Bruce D Walker; Anthony P West; Pamela J Bjorkman; Michel C Nussenzweig Journal: Sci Transl Med Date: 2017-01-18 Impact factor: 17.956
Authors: Peter Rusert; Roger D Kouyos; Claus Kadelka; Hanna Ebner; Merle Schanz; Michael Huber; Dominique L Braun; Nathanael Hozé; Alexandra Scherrer; Carsten Magnus; Jacqueline Weber; Therese Uhr; Valentina Cippa; Christian W Thorball; Herbert Kuster; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Jacques Fellay; Roland R Regoes; Huldrych F Günthard; Alexandra Trkola Journal: Nat Med Date: 2016-09-26 Impact factor: 53.440